Summary of Study ST000455

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000351. The data can be accessed directly via it's Project DOI: 10.21228/M8PC8X This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Download binned data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000455
Study TitleUtilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs (part II)
Study SummaryThis pilot study will use broad spectrum metabolomics to study the tumorigenesis process of fibroblasts to desmoids by investigating paired desmoid and fibroblast cell lines, in addition to unaffected fibroblast cells. Additionally, this pilot study will explore the effects of two of the active drugs identified on the desmoid and fibroblast cells.
RTI International
Last NameMercier
First NameKelly
Address3040 E. Cornwallis Road
Submit Date2016-08-31
Raw Data AvailableYes
Raw Data File Type(s)1r
Analysis Type DetailNMR
Release Date2017-12-06
Release Version1
Kelly Mercier Kelly Mercier application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000351
Project DOI:doi: 10.21228/M8PC8X
Project Title:Utilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs
Project Summary:Desmoid tumors (DT) are locally invasive soft tissue growths with no directed therapies currently. While two genes (β-catenin and adenomatous polyposis coli) have been found in patients who develop desmoids, it is unclear how these mutations and other downstream mechanisms lead to desmoid tumorigenesis. Extensive research has been explored in the molecular biology of desmoids; however, the use of metabolomics to understand the how the low molecular weight complements of cells, tissues, and biological fluids are perturbed by this highly localized disease. Additionally, the Desmoid Collaboration for a Cure has identified 45 active drugs against primary cell lines. It is unclear how these therapies perturb the metabolome, outside the Wnt and notch pathways.
Institute:RTI International
Last Name:Mercier
First Name:Kelly
Address:3040 E. Cornwallis Road